| Literature DB >> 29036692 |
Kazuya Takeda1, Kentaro Takanami2, Yuko Shirata1, Takaya Yamamoto1, Noriyoshi Takahashi1, Kengo Ito1, Kei Takase2, Keiichi Jingu1.
Abstract
We evaluated the reproducibility and predictive value of texture parameters and existing parameters of 18F-FDG PET/CT images in Stage I non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT). Twenty-six patients with Stage I NSCLC (T1-2N0M0) were retrospectively analyzed. All of the patients underwent an 18F-FDG PET/CT scan before treatment and were treated with SBRT. Each tumor was delineated using PET Edge (MIM Software Inc., Cleveland, OH), and texture parameters were calculated using open-source code CGITA. From 18F-FDG PET/CT images, three conventional parameters, including maximum standardized uptake value (SUV), metabolic tumor volume (MTV) and total lesion glycolysis (TLG), and four texture parameters, including entropy and dissimilarity (derived from a co-occurrence matrix) and high-intensity large-area emphasis (HILAE) and zone percentage (derived from a size-zone matrix) were analyzed. Reproducibility was evaluated using two independent delineations conducted by two observers. The ability to predict local control (LC), progression-free survival (PFS) and overall survival (OS) was tested for each parameter. All of the seven parameters except zone percentage showed good reproducibility, with intraclass correlation coefficient values >0.8. In univariate analysis, only HILAE was a significant predictor for LC. Histology, dose fractionation, and maximum SUV were associated with PFS, and histology and dose fractionation were associated with OS. We showed that texture parameters derived from 18F-FDG PET/CT were reproducible and potentially beneficial for predicting LC in Stage I lung cancer patients treated with SBRT.Entities:
Keywords: 18F-FDG PET/CT; lung cancer; prognostic factor; radiomics; stereotactic body radiotherapy (SBRT); texture analysis
Mesh:
Substances:
Year: 2017 PMID: 29036692 PMCID: PMC5710655 DOI: 10.1093/jrr/rrx050
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Fig. 1.A flowchart of texture analysis. A semi-automated delineation tool PET Edge (MIM Software Inc., Cleveland, OH) was used for tumor delineation. For parameter calculation, CGITA, developed by Fang et al., was used.
Patient characteristics
| Number of patients | ||
|---|---|---|
| Sex | Female | 6 (23%) |
| Male | 20 (77%) | |
| Age | 78.5 (48–88)a | |
| Location | Upper lobe | 19 (73%) |
| Middle lobe | 1 (4%) | |
| Lower lobe | 6 (23%) | |
| Tumor diameter | 24 (10–39)a | |
| Histology | Adeno | 10 (38%) |
| SCC | 7 (27%) | |
| NSCLC, NOS | 2 (8%) | |
| Unknown | 7 (27%) | |
| Performance status | 0 | 10 (38%) |
| 1 | 13 (50%) | |
| 2 | 2 (8%) | |
| 3 | 1 (4%) | |
| Operability | Operable | 13 (50%) |
| Inoperable | 13 (50%) | |
| Dose fractionation | 4 | 13 (50%) |
| 8 | 10 (38%) | |
| 15 | 3 (12%) | |
| BED10 | ≥100 | 17 (65%) |
| <100 | 9 (35%) |
aShown as median with ranges. SCC = squamous cell carcinoma, Adeno = adenocarcinoma, BED10 = biological equivalent dose calculated with an α/β ratio = 10.
Intraclass correlation analysis between two different observers
| ICC | |
|---|---|
| Maximum SUV | 1.00 |
| Metabolic tumor volume | 0.92 |
| Total lesion glycolysis | 0.99 |
| Entropy | 0.81 |
| Dissimilarity | 0.95 |
| HILAE | 0.94 |
| Zone percentage | 0.66 |
ICC = intraclass correlation coefficient, SUV = standard uptake value, HILAE = high intensity large area emphasis.
Univariate analysis for local control, progression-free survival and overall survival with a log-rank test
| LC | PFS | OS | ||
|---|---|---|---|---|
| Sex | Female vs male | 0.50 | 0.46 | 0.06 |
| Age | ≥78.5 vs <78.5† | 0.58 | 0.21 | 0.19 |
| Tumor diameter | ≥30 mm vs <30 mm | 0.31 | 0.07 | 0.35 |
| Location of the tumor | Lower vs upper/middle lobe | 0.62 | 0.87 | 0.81 |
| Histology | SCC vs others | 0.43 | ||
| Performance status | ≥2 vs <2 | 0.89 | 0.47 | 0.78 |
| Operability | Inoperable vs operable | 0.68 | 0.72 | 0.45 |
| Number of fractions | 4 vs 8 or 15 | 0.15 | ||
| BED10 | ≥100 Gy vs <100 Gy | 0.52 | 0.07 | 0.62 |
| Maximum SUV | ≥8.18 vs <8.18† | 0.78 | 0.08 | |
| Metabolic tumor volume | ≥5.99 vs <5.99† | 0.55 | 0.41 | 0.87 |
| Total lesion glycolysis | ≥23.4 vs <23.4† | 0.81 | 0.14 | 0.31 |
| Entropy | ≥–58.1 vs <–58.1† | 0.55 | 0.39 | 0.72 |
| Dissimilarity | ≥2393 vs <2393† | 0.81 | 0.22 | 0.36 |
| HILAE | ≥1785 vs <1785† | 0.16 | 0.31 | |
| Zone percentage | ≥0.41 vs <0.41† | 0.51 | 0.60 | 0.64 |
Asterisk (*) shows significance with P value <0.05 (shown in bold), and dagger (†) represents a median. LC = local control, PFS = progression-free survival, OS = overall survival, SCC = squamous cell carcinoma, Adeno = adenocarcinoma, BED10 = biological equivalent dose calculated with an α/β ratio = 10, SUV = standard uptake value, HILAE = high-intensity large-area emphasis.
Fig. 2.Kaplan–Meyer curves for parameters considered to be significant in log-rank test. HILAE = high-intensity large-area emphasis, SCC = squamous cell carcinoma, SUV = standard uptake value.
Fig. 3.Evaluation of the predictive value of high-intensity large-area emphasis (HILAE) for local control by Receiver operating characteristic (ROC) analysis. AUC = area under the ROC curve.